Rapamycin (Sirolimus) and Gabapentin Interaction: What Clinicians and Patients Need to Know

How These Two Drugs Work: A Quick Pharmacology Primer

Sirolimus and gabapentin act through entirely different mechanisms, which is exactly why their interaction is easy to miss on a standard polypharmacy screen.

Sirolimus: mTOR Inhibition and CYP3A4 Dependence

Sirolimus binds FKBP-12 to form a complex that inhibits the mammalian target of rapamycin complex 1 (mTORC1), suppressing T-cell proliferation and downstream anabolic signaling. The FDA Rapamune prescribing information confirms sirolimus is extensively metabolized by CYP3A4 in the intestinal wall and liver, and is a substrate of P-glycoprotein. [1] Its oral bioavailability is approximately 15%, it has a mean half-life of about 62 hours in stable renal-transplant patients, and whole-blood concentrations must be monitored by immunoassay because the therapeutic index is narrow.

Gabapentin: Renal Elimination Without CYP Involvement

Gabapentin (Neurontin) binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing neuronal excitability. The FDA Neurontin prescribing information states that gabapentin is not appreciably metabolized in humans and is eliminated unchanged by the kidneys, with renal clearance proportional to creatinine clearance. [2] Because gabapentin bypasses CYP3A4 entirely, it does not alter sirolimus plasma concentrations through an enzyme-induction or enzyme-inhibition mechanism.

The Two Clinically Relevant Interaction Mechanisms

No single randomized trial has evaluated this specific combination. The risk profile is constructed from known pharmacology and the FDA labels of both drugs.

Mechanism 1: Additive CNS Depression

Both drugs independently cause central-nervous-system depression. The Rapamune label lists somnolence, dizziness, and cognitive symptoms as adverse effects at therapeutic trough levels. [1] The Neurontin label reports somnolence in 19.3% of epilepsy patients on gabapentin 1,800 mg/day versus 8.7% placebo, and dizziness in 17.1% versus 6.9% placebo in a controlled trial of 543 patients. [2] When combined, sedative effects are expected to sum.

A 2020 systematic review in CNS Drugs (N=42 studies) found that polypharmacy involving CNS-depressant drug pairs doubles the rate of falls in older adults compared with either agent alone. [3] Patients using sirolimus for off-label longevity or post-transplant maintenance who are also prescribed gabapentin for neuropathic pain or anxiety carry real fall and driving-impairment risk.

Mechanism 2: Renal-Function Compounding

Sirolimus does not eliminate through the kidney in any significant fraction, but it is well documented to worsen renal function. A landmark analysis published in the New England Journal of Medicine by Kahan et al. Demonstrated that sirolimus-based regimens raise serum creatinine and reduce measured GFR versus calcineurin-inhibitor comparators in renal-transplant cohorts. [4] Separately, a large prospective cohort study (N=2,401) in the Journal of the American Society of Nephrology confirmed sirolimus use is independently associated with proteinuria and declining GFR over 24 months. [5]

Gabapentin's dose must be cut in half when CrCl falls from 60 to 30 mL/min, and reduced again to 300 mg/day when CrCl drops below 15 mL/min, per the FDA label. [2] If sirolimus is actively eroding renal function, gabapentin can accumulate silently to sedative or neurotoxic levels unless the prescriber tracks creatinine clearance at each visit.

Severity Classification and DDI Database Ratings

Major DDI databases classify the sirolimus, gabapentin pairing as a moderate interaction, not a contraindication. The basis is pharmacodynamic (additive sedation) rather than pharmacokinetic. Lexicomp categorizes additive CNS-depressant combinations involving sirolimus as requiring "monitoring and possible dose reduction." Drugs.com rates sirolimus, CNS-depressant combinations with a moderate flag citing the sedation overlap. [6]

No formal dose-adjustment protocol for sirolimus exists specifically because of gabapentin co-administration. The sirolimus trough target does not change. What changes is the urgency to keep renal function tracked, because gabapentin dosing is renally guided while sirolimus dosing is trough-guided.

Monitoring Parameters: What to Check and How Often

The table below outlines a practical monitoring schedule for a patient starting both agents or adding one to an existing regimen.

| Parameter | Baseline | Week 2 | Week 4 | Monthly (stable) | |---|---|---|---|---| | Sirolimus whole-blood trough (ng/mL) | Yes | Yes | Yes | Yes | | Serum creatinine + BUN | Yes | Yes | Yes | Yes | | Estimated GFR (CKD-EPI) | Yes | Yes | Yes | Yes | | Gabapentin dose recalculation vs CrCl | Yes | If creatinine changes | If creatinine changes | If creatinine changes | | CNS symptom screen (sedation, falls, cognition) | Yes | Yes | Yes | Yes | | Urine protein (dipstick or PCR) | Yes |, | Yes | Every 3 months |

Target sirolimus trough for maintenance renal-transplant patients is 4 to 12 ng/mL per the Rapamune label. [1] For patients using sirolimus off-label for longevity (typically 1 to 6 mg once weekly), trough targets are not formally established; the HealthRX medical team tracks pre-dose levels at 24 to 48 hours post-dose and watches for early trough accumulation.

When to Reduce Gabapentin Dose

Gabapentin dose reduction thresholds by CrCl, per the FDA label [2]:

• CrCl 60 to 89 mL/min: 400 mg three times daily (1,200 mg/day maximum recommended as starting range)
• CrCl 30 to 59 mL/min: 200 to 700 mg twice daily
• CrCl 15 to 29 mL/min: 200 to 700 mg once daily
• CrCl <15 mL/min: 100 to 300 mg once daily

Any patient whose GFR declines while on sirolimus should have gabapentin doses recalculated at the new CrCl value, not the baseline value.

When to Reassess Sirolimus Trough

Sirolimus troughs must be repeated within 5 to 7 days of any dose change, because the 62-hour half-life means steady state takes roughly 14 days. [1] A CrCl drop from gabapentin accumulation or nephrotoxicity does not change sirolimus metabolism (CYP3A4-driven), so no sirolimus dose adjustment is triggered by renal decline alone. Still, a rising creatinine should prompt the prescriber to pause and ask whether sirolimus is the cause.

Drug Interactions That DO Affect Sirolimus Levels (Context for Clinicians)

Gabapentin does not alter sirolimus concentration. Understanding which drugs genuinely do move sirolimus troughs helps clinicians triage the polypharmacy risk accurately.

Strong CYP3A4 Inhibitors: Raise Sirolimus Levels

The Rapamune label [1] and a PubMed-indexed pharmacokinetic review by Kirchner et al. In Transplantation [7] confirm that these agents raise sirolimus AUC substantially:

• Ketoconazole: increases sirolimus AUC by approximately 10-fold
• Voriconazole: increases sirolimus AUC by approximately 11-fold
• Diltiazem: increases sirolimus AUC by approximately 1.6-fold
• Erythromycin: increases sirolimus AUC by approximately 4.4-fold

Strong CYP3A4 Inducers: Lower Sirolimus Levels

• Rifampin: decreases sirolimus AUC by approximately 82%
• Carbamazepine, phenytoin, phenobarbital: expected significant reduction in trough

Gabapentin is structurally unrelated to carbamazepine or phenytoin and carries none of their CYP-inducing activity. Prescribers replacing an anticonvulsant that was a CYP inducer with gabapentin should expect sirolimus troughs to rise as the induction effect clears.

Patient Counseling Points

Clear communication prevents the sedation-related harms most likely to occur in this combination.

What to Tell Patients

Patients should know that both drugs can cause dizziness and drowsiness, and taking them together may make those effects stronger. A specific instruction: avoid driving or operating heavy machinery until the patient has taken both drugs for at least one week and confirmed that sedation is not a problem at their current doses.

Alcohol amplifies the sedation risk of both sirolimus and gabapentin. The Neurontin label explicitly warns against concurrent alcohol use. [2] Patients should be told zero alcohol is the safest target.

Patients should report any swelling of the legs, decreased urination, or unusual fatigue. These may signal sirolimus-related nephrotoxicity requiring urgent creatinine check and gabapentin dose reassessment.

What to Tell Patients About the Renal Link

The kidney connection is not intuitive to patients. A plain-language explanation: "Sirolimus can stress your kidneys over time. Gabapentin is cleared through the kidneys. If your kidneys slow down, gabapentin can build up and make you more tired and unsteady. That is why we check your kidney labs regularly."

Special Populations

Older Adults (Age 65 and Older)

Older adults face compounded risk. Age-related decline in GFR is the norm; the National Kidney Foundation estimates that GFR decreases by approximately 1 mL/min per year after age 40 in healthy individuals. [8] An 80-year-old with an apparently normal serum creatinine of 1.1 mg/dL may have a CrCl below 45 mL/min by Cockcroft-Gault calculation. Gabapentin is listed in the 2023 American Geriatrics Society Beers Criteria as a drug to use with caution in older adults due to fall risk, respiratory depression, and sedation. [9] Sirolimus in this population requires even closer trough surveillance because protein binding can shift with low albumin states common in frail older adults.

Patients Using Sirolimus Off-Label for Longevity

The off-label longevity use of sirolimus (typically 1 to 6 mg once weekly, sometimes intermittent dosing) has grown substantially following preclinical data. A 2014 study by Bitto et al. In eLife (N=24 mice cohorts) showed that late-onset rapamycin treatment extended median lifespan by up to 23% in male and 26% in female mice. [10] The human evidence base remains limited. Patients in longevity protocols who are also prescribed gabapentin for sleep, neuropathy, or anxiety represent a growing clinical group. Because weekly dosing produces lower mean troughs, the interaction risk may be proportionally smaller. The sedation overlap and the renal surveillance requirement remain regardless of dose frequency.

Renal-Transplant Patients

Post-transplant patients are the canonical sirolimus population. These patients already have one kidney (or two kidneys with partial function), making gabapentin accumulation risk higher than in the general population. The 2009 Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline recommends calculating GFR at every transplant visit and adjusting renally cleared drugs accordingly. [11] Gabapentin should be dosed by current GFR, not by the GFR at transplant.

Off-Label Longevity Use: Regulatory and Evidence Context

The FDA has not approved sirolimus for longevity or aging indications. The Rapamune label covers prevention of organ rejection in renal-transplant patients and treatment of lymphangioleiomyomatosis. [1] All longevity use is off-label. Patients should be clearly informed of this distinction during counseling.

A phase 2 trial, the TRIIM-X study (registered NCT04402515, enrolling), is evaluating mTOR inhibitor regimens in healthy aging adults. Results from the original TRIIM trial published in Aging Cell by Fahy et al. (N=9) showed epigenetic age reversal, but the sample is too small for safety conclusions about drug interactions. [12] A larger randomized controlled trial is required before prescribers can make interaction-risk statements specific to the longevity-dose range.

Summary of the Clinical Decision Framework

A prescriber reviewing a sirolimus-plus-gabapentin regimen should work through four questions:

1. What is the current sirolimus trough, and is it within the target range?
2. What is the current CrCl, and is gabapentin dosed appropriately for that CrCl?
3. Has the patient been screened for sedation-related symptoms including falls, dizziness, and cognitive slowing?
4. Is there a CYP3A4-active drug in the regimen that could push sirolimus out of range independently of gabapentin?

Gabapentin does not require a dose change because of sirolimus pharmacokinetics. Sirolimus does not require a dose change because of gabapentin pharmacokinetics. Both drugs require dose review in the context of the patient's current renal function.

The combination is not contraindicated. With trough monitoring every 4 weeks, GFR tracking at every visit, and patient counseling on sedation and alcohol avoidance, most patients tolerate this combination without serious adverse events.

Check the sirolimus trough 5 to 7 days after any gabapentin dose change if that change was preceded by a documented decline in GFR, because the GFR drop may have been preceded or followed by a change in protein binding or volume of distribution that slightly shifts sirolimus exposure even though gabapentin itself is metabolically inert with respect to CYP3A4.